Solian (amisulpride) is a benzamide antipsychotic dosed across a wide range, from 50 mg for predominant negative symptoms to 1200 mg for acute psychosis, and licensed generic amisulpride tablets now sit alongside the originator on most tender lists.
Solian (amisulpride), originated by Sanofi, is a dopamine D2/D3 antagonist used across acute and chronic schizophrenia. M Care Exports is a merchant exporter: we source Solian and licensed generic amisulpride tablets through India's WHO-GMP manufacturer network and dispatch on quote against a hospital, wholesaler or MoH tender specification, never from our own manufacturing.
Also marketed as Barhemsys.
Amisulpride exporter and bulk supplier from India.
For hospital and tender-desk orders, M Care quotes amisulpride tablets against buyer specification: brand (Solian) or generic, strength (50 mg, 100 mg, 200 mg, 400 mg) and destination-market regulatory documentation. Because dosing differs sharply between the negative-symptom regimen (50-300 mg/day) and the acute-psychosis regimen (400-1200 mg/day), we confirm which indication a tender is quoting against before packing, so the strength mix matches the buyer's own dosing protocol rather than a generic assortment.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Substituted benzamide; atypical antipsychotic; dopamine D2/D3 receptor antagonist, sourced and documented for export.
Amisulpride is a substituted benzamide, an atypical antipsychotic that blocks dopamine D2 and D3 receptors. At low doses it preferentially blocks presynaptic autoreceptors, which is why UK labelling carries a distinct 50-300 mg/day range for predominant negative symptoms, separate from the higher-dose regimen used for positive psychotic symptoms.
Per the UK SmPC, amisulpride is licensed for acute and chronic schizophrenic disorders in which positive symptoms (delusions, hallucinations, thought disorder) and/or negative symptoms (blunted affect, emotional and social withdrawal) predominate, including patients with predominant negative symptoms. Destination-country labelling should be checked against this before a tender quote is finalised.
Solian and generic amisulpride are supplied as 50 mg, 100 mg, 200 mg and 400 mg film-coated tablets, taken orally, alongside a 100 mg/mL oral solution licensed in the UK for patients who cannot swallow tablets. A separate 2.5 mg/mL intravenous formulation (Barhemsys in the US) exists for postoperative nausea and vomiting; M Care's oral tablet line and this injectable indication are distinct products and are quoted separately.
Active ingredient
amisulpride. Substituted benzamide; atypical antipsychotic; dopamine D2/D3 receptor antagonist.
Forms and strengths
50 mg film-coated tablet; 100 mg film-coated tablet; 200 mg film-coated tablet; 400 mg film-coated tablet; 100 mg/mL oral solution; 2.5 mg/mL injection.
Indications
Benzamide antipsychotic licensed for acute and chronic schizophrenic disorders with predominant positive and/or negative symptoms, dosed across a wide range depending on symptom target.
Administration
oral. Film-coated tablet; oral solution.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for amisulpride are mainly mental-health and general hospital pharmacies, MoH tender desks running psychiatric-formulary procurement across the GCC and Africa, licensed pharmaceutical wholesalers and importers, and NGO or public mental-health programme procurement in markets where local registration is in place. Because both branded Solian and generic amisulpride tablets are licensed in most of our served markets, tender desks often request quotes on both to compare against their formulary rules before award.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on amisulpride.
Amisulpride's dosing split matters at the dispensing bench: 50-300 mg/day for predominant negative symptoms, but 400-800 mg/day for acute psychotic episodes, rising to a maximum of 1200 mg/day in individual cases per the UK SmPC. Doses up to 400 mg can be given once daily; above that, split into two doses. A pharmacy quoting a mixed adult caseload should stock the 100 mg and 400 mg strengths together to cover both regimens without tablet-splitting, which the label does not endorse for film-coated strengths below 400 mg.
Renal impairment needs an explicit dose cut, not a general caution: halve the dose at creatinine clearance 30-60 mL/min, and cut it to a third at 10-30 mL/min, since amisulpride is predominantly renally eliminated with minimal hepatic metabolism. Elderly patients are not recommended for treatment at all; if unavoidable, caution is required for hypotension and sedation risk.
Amisulpride carries a QT-prolongation warning on the label, so baseline ECG and electrolyte correction (particularly potassium and magnesium) are worth flagging at intake, alongside avoidance of other QT-prolonging co-medication. It is also strongly prolactin-elevating, so it is contraindicated in prolactin-dependent tumours and phaeochromocytoma, and amenorrhoea or galactorrhoea on therapy should prompt a prolactin check rather than dose escalation. As an oral solid (or oral solution), amisulpride needs no cold chain or reconstitution.
The documentation pack a regulator actually asks for.
As an oral solid dosage form, amisulpride tablets travel on standard ambient-temperature logistics rather than the cold-chain lanes we validate for biologics; UK-licensed product is stored below 25 degrees C in its original packaging with a 24-month shelf life, and we align dispatch batches to give buyers meaningful remaining shelf life on arrival. What tender desks need alongside standard import documentation is confirmation of which strength mix matches their dosing protocol, given the wide range between the negative-symptom and acute-psychosis regimens.
On the brand-versus-generic question, Solian remains the Sanofi-originated brand licensed across the UK, Ireland, Australia, South Africa and other markets, and multiple generic amisulpride tablet lines are separately licensed in the UK under the same SmPC framework, so buyers genuinely have a brand-or-generic choice. M Care quotes either against the tender specification and destination-market registration status, since amisulpride is not FDA-approved for any oral psychiatric indication in the US; the only US-approved amisulpride product is the unrelated Barhemsys intravenous formulation for postoperative nausea and vomiting, which we do not present as interchangeable with the oral schizophrenia product.
For the import route itself, step by step from import licence to customs release, see importing branded medicines from India: the licensed route.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside amisulpride.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for amisulpride.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Amisulpride supply, the specific questions.
Is there a generic version of Solian (amisulpride)?
Yes. Multiple generic amisulpride tablet lines are separately licensed in the UK alongside Sanofi's originator brand Solian, under the same SmPC framework and strengths. M Care checks local registration status before quoting brand or generic against a specific tender.
Can M Care supply Solian to our market?
Yes, on an import basis. We source Solian through licensed Indian distribution channels and dispatch against your import authorisation and destination-market registration requirements.
What strengths of amisulpride tablets are available?
50 mg, 100 mg, 200 mg and 400 mg film-coated tablets, matching the UK-licensed Solian and generic amisulpride range, plus a 100 mg/mL oral solution for patients who cannot swallow tablets. Tell us your dosing protocol and we quote the strength mix accordingly.
Why does amisulpride have such a wide dosing range?
Amisulpride is dosed differently by symptom target: 50-300 mg/day for predominant negative symptoms, but 400-800 mg/day, up to a maximum 1200 mg/day, for acute psychotic episodes. Confirm which indication your protocol is quoting against so we pack the correct strength mix.
Is amisulpride approved in the United States for schizophrenia?
No. Amisulpride is not FDA-approved for any oral psychiatric indication. The only US-approved amisulpride product is an unrelated intravenous formulation (Barhemsys) for postoperative nausea and vomiting, which is a separate product from the oral tablets M Care supplies for schizophrenia.
Does amisulpride need cold-chain shipping?
No. Amisulpride tablets and oral solution are stored below 25 degrees C in original packaging with a 24-month shelf life, so they ship and store as standard ambient pharmaceuticals rather than requiring validated cold-chain lanes.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-09-11.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.